Immunovant (NASDAQ:IMVT) has received positive analyst ratings in the last quarter, with 7 bullish and 6 somewhat bullish ratings out of 13 total, and no indifferent or bearish ratings. The average price target is $43.69, representing an implied upside from the current price of $39.13. This target has increased by 36.53% from the previous target of $32.00. Analysts use various data sources to provide these ratings, which are opinions and can vary in accuracy.